ClinicalTrials.gg
CompletedNCT04653597NICOUpdated Jul 17, 2023

Non-invasive Airway Management of Comatose Poisoned Emergency Patients

A Phase 3 interventional study of Close monitoring and Endotracheal intubation in Poisoning, Consciousness, Level Altered and Comatose, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-17.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A decreased level of consciousness is a common reason for presentation to the emergency department (ED) and is often the result of intoxication (up to 1% of all ED visits and 3% of ICU admission). In France, approximately 165 000 poisoned patients are managed each year. Originally developed in head injured patients, the Glasgow Coma Scale (GCS) is a validated reproducible score evaluating the level of consciousness: a GCS ≤ 8 is strongly associated with reduced gag reflex and increased incidence of aspiration pneumonia. Although recommended for patients with traumatic brain injury and coma, it remains unknown whether the benefit of an invasive management of airways with sedation, intubation and mechanical ventilation should be applied to other causes of coma in particular for acute poisoned patients. The investigator hypothesize that a conservative management with close monitoring without immediate endotracheal intubation of these patients is effective and associated with less in-hospital complications (truncated at 28 days) compared to routine practice management (in which the decision of immediate intubation is left to the discretion of the emergency physician).

Read the detailed description

A decreased level of consciousness is a common reason for presentation to the emergency department (ED) and is often the result of intoxication (up to 1% of all ED visits and 3% of intensive care unit (ICU) admission). In France, approximately 165 000 poisoned patients are managed each year.1 Originally developed in head injured patients, the Glasgow Coma Scale (GCS) is a validated reproducible score evaluating the level of consciousness - a GCS ≤ 8 is associated with reduced gag reflex and increased incidence of aspiration pneumonia (with an adjusted odds ratio of 2.32, 95%CI =1.60 to 3.33). However, whether this risk of aspiration pneumonia (AP) may be decreased by early intubation is unknown, and no difference in the risk of AP was reported between patients that were intubated early and patients who were not.

Although it is well established that in trauma patients, a GCS ≤ 8 mandates airway management by endotracheal intubation, it remains unknown whether this strategy should be applied to other etiologies of coma, in particular for acute poisoned patients. Tracheal intubation and mechanical ventilation allow to prevent aspiration pneumonia, to optimize oxygenation and gas exchange.

Investigators will include patients with a decreased level of consciousness (defined by a GCS of 8 or less) caused by acute intoxication (alcohol, recreative drugs, or other prescription drugs (with the exception intoxication with cardiotropic drugs, e.g. beta blockers, calcium channel inhibitor, angiotensin conversion enzyme)). These patients will be included at the initial stage of their management: in the ED, or out of hospital with a pre-hospital emergency physician. Patients with clear proven benefit of intubation will be excluded : patients in shock, patients with suspicion of brain lesion, seizure related with poisoning, visualization of regurgitation of gastric content or sign of respiratory distress. Conservative airway management. Patients will be conservatively managed, i.e. close monitoring and no intubation and mechanical ventilation unless the patient presents a clinical event that needs intubation (shock, sign of respiratory distress, visualization of regurgitation or seizure).

Acute poisoning is a common reason for presentation to the ED or MICU intervention (up to 1% of all ED visits and 3% of intensive care unit (ICU) admission). These patients are often intubated (reported rate ranging from 20 to 50% in different cohort studies), when their GCS is below 8, in order to protect their airways. However there is currently no clear demonstration of its efficacy in this specific target population, while it is known that intubation is associated with morbidity and mortality.

Intubated patients need subsequent intensive care unit admission and invasive monitoring, and this can be associated with increased risk of pulmonary complications, length of hospital-stay, nosocomial infections and cost. In a context of expenditures control in health care, appropriate intensive care resource utilization is an important issue. When considering the increasing demand for intensive care among emergency patients, the importance of health care resource allocation and expenditure control, and the possible absence benefit of intubation and intensive care, an endotracheal airway management of poisoned coma patients might be detrimental.

Thus, if our hypothesis is demonstrated, the results of NICO study will change practice and guidelines for management of acute coma poisoned patients, with less exposure to the morbidity of endotracheal intubation and associated with decrease of ICU stay, and reduction of their health costs.

02

Conditions studied

  • Poisoning
  • Consciousness, Level Altered
  • Comatose

Keywords

  • ED
  • ICU
  • MICU
  • Coma
  • Comatose poisoning
  • intubation
  • Endotracheal intubation
  • GCS
  • Glasgow Coma Scale
03

In context

Poisoning

98 studies on the registry are indexed under Poisoning; 16 are open to participants now.

This study's enrollment of 237 is above the median of 46 across 52 interventional studies indexed under Poisoning.

Browse Poisoning studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Clinical suspicion of acute poisoning (either alcohol, drug or medication)
  3. Decreased level of consciousness with a GCS ≤ 8 assessed by an emergency physician either in the ED or in the out of hospital field with the mobile intensive care unit (MICU).
  4. Written signed by the patient / the trustworthy person / family member / close relative or inclusion in case of emergency
  5. Patients affiliated to French social security ("AME" excepted)

Exclusion criteria

Exclusion Criteria:

  1. Respiratory failure (SpO2 \< 90% with oxygen provided by nasal cannula (≤ 4 l/min.), clinical signs of respiratory distress)
  2. Sustained systolic blood pressure \< 90 mmHg despite fluid resuscitation of 1 liter of critalloid
  3. Witnessed seizure
  4. Acute cerebral aggression (Traumatic brain injury, intracranial hematoma, stroke)
  5. Suspected Cardiotropic drugs poisoning (beta blockers, calcium channel inhibitor, angiotensin conversion enzyme), QRS or enlargement on .
  6. Suspected sole intoxication with toxic for which there is an antidote
  7. Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom
  8. Known Pregnant women and breast feeding woman
  9. Participation in another intervention trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
237 participants (actual)

Study arms

  • Experimental
    Conservative airway management

    decision to intubate will be withheld as long as the patient's state allows it. The patient will be closely monitored and decision of intubation will be made upon presence of regurgitation, seizure, shock, or sign of respiratory distress.

    Procedure: Close monitoring

  • Other
    Routine practice

    decision of intubation left at the discretion of the emergency physician

    Procedure: Endotracheal intubation

Interventions

  • ProcedureClose monitoring

    surveillance every 30 minutes of blood pressure, SpO2, respiratory rate, heart rate and GCS until the patient recovers a GCS\>8 or responds adequately to a simple order

  • ProcedureEndotracheal intubation

    invasive airway management in order to avoid risk of pulmonary aspiration

06

What researchers measure

Primary outcomes

  1. Hierarchical composite endpoint of (truncated at 28 days): - In hospital death

    this endpoint will be reported using both the Finkelstein model (Finkelstein Stat med 1999; Beitler JAMA 2019) and the win ratio methods (Pocok Eur H J 2016), with priority listed in this order from highest to lowest. Patients will be followed until hospital discharge (or truncated at 28 days if still hospitalized) and data collected in the electronic health record the investigator with the help of a clinical research technician.

    Time frame: at 28 days

  2. Hierarchical composite endpoint of (truncated at 28 days):- Length of ICU stay

    this endpoint will be reported using both the Finkelstein model (Finkelstein Stat med 1999; Beitler JAMA 2019) and the win ratio methods (Pocok Eur H J 2016), with priority listed in this order from highest to lowest. Patients will be followed until hospital discharge (or truncated at 28 days if still hospitalized) and data collected in the electronic health record the investigator with the help of a clinical research technician.

    Time frame: at 28 days

  3. Hierarchical composite endpoint of (truncated at 28 days): - Length of hospital stay

    this endpoint will be reported using both the Finkelstein model (Finkelstein Stat med 1999; Beitler JAMA 2019) and the win ratio methods (Pocok Eur H J 2016), with priority listed in this order from highest to lowest. Patients will be followed until hospital discharge (or truncated at 28 days if still hospitalized) and data collected in the electronic health record the investigator with the help of a clinical research technician.

    Time frame: at 28 days

Secondary outcomes

  1. In-hospital death (truncated at 28 days)

    number of included patients dead at 28 days after randomisation

    Time frame: at 28 days

  2. ICU length of stay (truncated at 28 days)

    number of day in ICU for each patient included since randomization

    Time frame: at 28 days

  3. Hospital length of stay (truncated at 28 days)

    number of day in hospitalization for each patient included since their randomization

    Time frame: at 28 days

  4. Proportion of patient with Mechanical ventilation at day 28

    number of patient included with mechanical ventilation 28 days after randomization

    Time frame: at 28 days

  5. Lenght of mechanical ventilation until hospital discharge or at day28

    Time frame: at 28 days

  6. Proportion of ICU admission

    number of patient included admitted to ICU during hospital stay

    Time frame: 28 days

  7. Proportion of rapid onset pneumonia

    number of patient included developing a rapid onset pneumonia during hospital stay

    Time frame: 28 days

  8. Adverse events from intubation (hypoxemia, dental trauma, regurgitation, cardiac arrest, intubation difficulty score (IDS) ≥ 5, hypotension or esophageal intubation)

    number of patient included developing an adverse events from intubation during hospital stay, and type of adverse events

    Time frame: 28 days

  9. total hospital costs (truncated at 28 days)

    cost of hospitalization for patient included in the study.

    Time frame: at 28 days

  10. total hospital cost consequence analysis (truncated at 28 days)

    cost of hospitalization for patient included in the study.

    Time frame: at 28 days

07

Study locations

1 site
  • Emergency department Hospital Pitié-Salpêtrière
    Paris, 75013, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04653597
Responsible party
Sponsor
First posted
Dec 4, 2020
Start date
May 16, 2021
Primary completion
Apr 12, 2023
Completion
Apr 12, 2023
Last update
Jul 17, 2023

Study contacts

Yonathan FREUND, PU-PH
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion